Beam Therapeutics Inc.
https://beamtx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Beam Therapeutics Inc.
Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Intellia To Take On Pfizer Blockbuster With Gene-Editing Therapy
After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.
Deals Or No Deals, J.P. Morgan Sets The Tone For 2022
No big buyouts were revealed during the annual J.P. Morgan Healthcare Conference for a third year in a row. Big pharma firms are in acquisition mode, but execs stress desire for easy integrations and scientific alliances.
Beam Anticipates Pfizer Deal Will Lead To Additional Partnerships
The $300m upfront payment should provide considerable runway for the base-editing company, which also plans multiple IND filings and enrolling the first patient in its sickle cell study this year.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Guide Therapeutics, Inc.